+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Peanut agglutinin in combination with CD19 monoclonal antibody has potential as a purging agent in myeloma

Peanut agglutinin in combination with CD19 monoclonal antibody has potential as a purging agent in myeloma

Experimental Hematology 19(8): 833-837

Administration of high-dose chemotherapy to patients with myeloma, followed by rescue with autologous bone marrow transplantation (ABMT), sometimes induces complete disease remission but relapse is usual. We have attempted to reduce the risk of relapse by selective in vitro removal of myeloma cells from the autologous graft. A combination of the (gal-galNac)-binding lectin peanut agglutinin (PNA), which binds all plasma cells, and the pan-B monoclonal antibody CD19 was assessed for purging marrow of myeloma cells and their putative precursors using a magnetic bead method. Preliminary experiments performed on a peripheral blood mononuclear cells spiked with fluorescent-labeled PNA+ Kirk tumor cells showed that a magnetic bead: target cell ratio of 40:1 resulted in a > 3-log reduction in PNA+ cells. This technique was then applied to 17 samples of myeloma bone marrow and to 18 samples of normal bone marrow spiked with PNA+ Kirk cells and CD19+ hairy cell leukemia cells. In each case all detectable plasma cells and CD19+ lymphocytes were effectively removed, and normal hemopoietic were effectively removed, and normal hemopoietic progenitor cell recovery was > 55%. This purging system deserves further study as a means of reducing relapse rates in myeloma patients treated by a combination of high-dose chemotherapy and ABMT.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 007637316

Download citation: RISBibTeXText

PMID: 1714405

Related references

A method for clinical purging of myeloma bone marrow using peanut agglutinin as an anti-plasma cell agent, in combination with CD19 monoclonal antibody. Bone Marrow Transplantation 10(6): 485-489, 1992

The synthesis of a peanut agglutinin-ricin A chain conjugate: potential as an in vitro purging agent for autologous bone marrow in multiple myeloma. Experimental Hematology 23(13): 1347-1352, 1995

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71(1): 13-29, 1988

Treatment of human b cell lymphoma with anti cd19 monoclonal antibody and with a combination of anti cd19 and il 2. Groopman, J E , D W Golde And C H Evans (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 100 Mechanisms Of Action And Therapeutic Applications Of Biologicals in Cancer And Immune Deficiency Disorders; Hoffman-La Roche-Smith Kline And French-Ucla Symposium, Keystone, Colorado, Usa, April 23-30, 1988 Xix+406p Alan R Liss, Inc : New York, New York, Usa Illus 293-304, 1989

A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent. Advances in Experimental Medicine and Biology 186: 833-841, 1985

Purging of myeloma cells from bone marrow using monoclonal antibodies and magnetic immunobeads in combination with 4-hydroperoxycyclophosphamide. Progress in Clinical and Biological Research 333: 311-319, 1990

Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. Blood 90(6): 2364-2375, 1997

Radioiodinated peanut agglutinin (PNA): a potential new tumor seeking agent. Kaku Igaku. Japanese Journal of Nuclear Medicine 23(1): 17-24, 1986

Radioiodinated peanut agglutinin a potential new tumor seeking agent. Kaku Igaku 23(1): 17-24, 1986

Peanut agglutinin purging and magnetic microspheres. Progress in Clinical and Biological Research 377: 139-146, 1992

Surface carbohydrate epitopes of Thy-1.1 and Thy-1.2 thymocytes are distinguished by a monoclonal antibody with a specificity common to peanut agglutinin. European Journal of Immunology 14(9): 787-793, 1984

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer ChemoTherapy and Pharmacology 73(1): 35-42, 2014

Immunochemical analysis of normal and neoplastic human mammary antigens using monoclonal antibody LICR-LON-M18 and peanut agglutinin. Protides of the Biological Fluids 31: 1001-1008, 1984

Large scale purging of myeloma bone marrow using pna and cd19 coated magnetic beads. Bone Marrow Transplantation 5(SUPPL 2): 93, 1990

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96(2): 284-290, 2011